3.1 Patients
Of the 70 patients that were recruited for trial eligibility, 43 patients (n=21 in the CSO group and n=22 in the placebo group) completed the study. Fig. 1 shows the study flow chart and a description of the causes for the loss to follow up.  Overall, 90.5% of participants were compliant with supplements, by the end of the trial. Any adverse effects were reported by patients with SFO and CSO consumption. There was no difference between groups in any of the demographic variables including gender, age, employment, education level, marital status and PAL.